Actinium Pharmaceuticals, Inc.

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the continued listing of the Company’s common stock on NYSE American, the Company’s compliance plan and the Plan Period, and the Company’s ability to regain compliance with the continued listing standards of the Company Guide. The Company can provide no assurance that it will make progress that NYSE Regulation determines to be satisfactory, that it will regain compliance during the Plan Period, or that subsequent developments will not adversely affect its ability to do so or to remain in compliance with other NYSE American continued listing standards. Forward-looking statements are subject to risks and uncertainties, including those described in the Company’s filings with the Securities and Exchange Commission, and the Company undertakes no obligation to update any forward-looking statement except as required by law.